Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.

Leukemia - 1 Sept 2018

Pavlasova Gabriela, Borsky Marek, Svobodova Veronika, Oppelt Jan, Cerna Katerina, Novotna Jitka, Seda Vaclav, Fojtova Miloslava, Fajkus Jiri, Brychtova Yvona, Doubek Michael, Pospisilova Sarka, Mayer Jiri, Mraz Marek

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody-Dependent Cell Cytotoxicity
Share to Antigens, CD20
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement System Proteins

Share to Cytotoxicity, Immunologic

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Receptors, Antigen, B-Cell

Share to Rituximab

Source

Identifiers

PMID: 30030508
DOI: 10.1038/s41375-018-0211-0

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.PMID 30030508Read ↗

Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progressionSemantic proximity Read ↗

CLL B cells with a bimodal CD38 expression pattern: persistence of bimodal populations despite effective therapy for B-CLL.Semantic proximity Read ↗

Rituximab resistance.Semantic proximity Read ↗

The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapySemantic proximity Read ↗

Improving Treatment Options for Patients With Double Refractory CLLSemantic proximity Read ↗

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.Semantic proximity Read ↗

Antibody therapy for chronic lymphocytic leukemia.Semantic proximity Read ↗

[Resistance to rituximab and CD20 mutation].Semantic proximity Read ↗

Therapeutic targeting of chronic lymphocytic leukemia by silver nanoparticlesSemantic proximity Read ↗

Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity.Semantic proximity Read ↗

Clonal analysis of IgM+ CD5+ CLL B cells.Semantic proximity Read ↗

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in Preclinical ModelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.